Preliminary Evaluation of the Safety and Immunogenicity of an Antimalarial Vaccine Candidate Modified Peptide (IMPIPS) Mixture in a Murine Model
| Autor: | Leonardo Roa, Magnolia Vanegas, Catalina Avendaño, Manuel E. Patarroyo, Diana Diaz-Arévalo, Jennifer Lambraño, Manuel A. Patarroyo, Hernando Curtidor |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Single drug dose Male Mouse Unclassified drug medicine.medical_treatment Protozoan Proteins Antibodies Protozoan Eritrocitos Malaria vaccine In vivo study Mice 0302 clinical medicine Malaria Falciparum Immunology and Allergy Medicine Drug safety Adjuvant Mice Inbred BALB C biology Immunogenicity Immunological tolerance General Medicine Repeated drug dose Erythrocyte 030220 oncology & carcinogenesis Vaccine immunogenicity Female Antibody Animal cell Merozoite Research Article lcsh:Immunologic diseases. Allergy Article Subject Immunology Plasmodium falciparum Antigens Protozoan Protozoal protein Article 03 medical and health sciences Drug synthesis Immune system Drug formulation Malaria Vaccines parasitic diseases Animals Animal experiment business.industry In vitro study medicine.disease biology.organism_classification Nonhuman Virology Malaria Immune protection inducing protein structure vaccine Humoral immunity Disease Models Animal 030104 developmental biology biology.protein Protein structure Plasmodium falciparum protein Immunization lcsh:RC581-607 business Peptides Controlled study |
| Zdroj: | Repositorio Institucional UDCA Universidad de Ciencias Aplicadas y Ambientales U.D.C.A instacron:Universidad de Ciencias Aplicadas y Ambientales U.D.C.A Journal of Immunology Research Repositorio EdocUR-U. Rosario Universidad del Rosario instacron:Universidad del Rosario Journal of Immunology Research, Vol 2019 (2019) |
| Popis: | Malaria continues being a high-impact disease regarding public health worldwide; the WHO report for malaria in 2018 estimated that ~219 million cases occurred in 2017, mostly caused by the parasite Plasmodium falciparum. The disease cost the lives of more than 400,000 people, mainly in Africa. In spite of great efforts aimed at developing better prevention (i.e., a highly effective vaccine), diagnosis, and treatment methods for malaria, no efficient solution to this disease has been advanced to date. The Fundación Instituto de Inmunología de Colombia (FIDIC) has been developing studies aimed at furthering the search for vaccine candidates for controlling P. falciparum malaria. However, vaccine development involves safety and immunogenicity studies regarding their formulation in animal models before proceeding to clinical studies. The present work has thus been aimed at evaluating the safety and immunogenicity of a mixture of 23 chemically synthesised, modified peptides (immune protection-inducing protein structure (IMPIPS)) derived from different P. falciparum proteins. Single and repeat dose assays were thus used with male and female BALB/c mice which were immunised with the IMPIPS mixture. It was found that single and repeat dose immunisation with the IMPIPS mixture was safe, both locally and systemically. It was observed that the antibodies so stimulated recognised the parasite’s native proteins and inhibited merozoite invasion of red blood cells in vitro when evaluating the humoral immune response induced by the IMPIPS mixture. Such results suggested that the IMPIPS peptide mixture could be a safe candidate to be tested during the next stage involved in developing an antimalarial vaccine, evaluating local safety, immunogenicity, and protection in a nonhuman primate model. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|